Pharmaceutical Cardiopulmonary diseases focussed US firm PhaseBio Pharmaceuticals on Friday announced that, after a strategic review of the VANGARD clinical trial of its investigational drug pemziviptadil that included an assessment of the evolving COVID-19 treatment landscape, feedback from the US Food and Drug Administration and an interim analysis of the VANGARD study data, it has elected to discontinue the trial. 26 October 2020